The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Now what have i been saying all along...................
every Trial Backs up Scancell ............... and the highlight of the day
PD-L1 was up-regulated in patients after vaccination, which is in line
with the vaccine VB10.16 inducing strong IFNg T cell responses
Synergy ...............
SCIB1 and Keytruda ... will play to each others strengths .......
as a comparison ...
https://pubmed.ncbi.nlm.nih.gov/31727676/
our other DNA vaccine ...
I know ....
anyway ... http://www.vaccibody.com/wp-content/uploads/2019/04/VB-C-01_to-web.pdf
all based on that ...
so the next question ........... after this deal
https://www.fiercebiotech.com/biotech/genentech-lays-310-million-wager-biontech-s-mrna-cancer-vaccine-platform
produced
https://www.fiercebiotech.com/biotech/roche-biontech-post-low-response-rate-cancer-vaccine-trial
and to me each time they do this .......... The COST of a deal goes Up ........... not down
wonder if you have factored that into your Bazooka valuation
Knowlesi ................
clearly you have missed the point that its a "personal vaccine" .........
Through this partnership, Genentech and Vaccibody will progress Vaccibody's investigational product, VB10.NEO, into clinical trials in the U.S. and in Europe. VB10.NEO, an individualized DNA-based neoantigen vaccine, uniquely targets encoded antigens to antigen presenting cells which are essential for generating potent T cell responses required for cancer therapy. The vaccine is designed to be produced on-demand according to the neoantigen profile of an individual patient. Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues, and are thus an attractive target for cancer immunotherapy as they may be recognized as foreign by the immune system.
""" uniquely targets encoded antigens to antigen presenting cells which are essential for generating potent T cell responses required for cancer therapy."""
when did they have the Uniquely bit ................... ?
Scancells targets direct to APC ......... and Cross presents
can you find that in the literature ?
perhaps not ..............
so basically what you are being told now .......... is Not .. new
Released 07:00:04 28 November 2019
so since Nov of last year can any one tell me what happened ?
and can any one explain ........... "defined reason"
AZN mentions patent
"""The trial of VAL201 has met its endpoints very well and the Company is now able to use the peptide in demonstrating the efficacy of the compound as a therapeutic product, addressing what is currently a poorly-served, yet very substantial commercial market.""
https://www.londonstockexchange.com/news-article/VAL/us-patent-grant-re-val201-metastatic-cancer/14326288?lang=en
Grace
as i have just explained ........... VAL itself is not capable of taking this forward .... which AZN has just stated
so without a JV ........ it all stops here ..
ATB
You ask about performing further Phase 1 studies with shareholder money, maybe to generate further data. Drilling down to those with specific forms of this disease, along with higher challenge doses, as you know, can easily be done during the Phase2b study. Why didn’t VAL do it now? Because they want to crack on, maximise the patent, and not delay the expansion of the dataset properly, which will require external investment. Furthermore, they know all too well that they’d like to examine the utility of VAL201 in other therapy areas – e.g. breast, uterine, and ovarian tumors. VAL could fiddle about with this ad infinitum to satisfy the desire to know what happens at 16mg/kg, for example, but they don’t need to yet. They want to write up what they have, find a partner
one last point
Of the 12 patients dosed with VAL201, 11 patients had sufficient PCWG2-relevant data collected across multiple cycles. 6 of these 11 have been categorised as responding throughout treatment. That is, when the treatment with VAL201 was halted for a defined reason, whether or not the 6 standard cycles had been completed, these patients showed no disease progression by PCWG2 criteria with stable disease.
what was the "defined reason"
"""That is, when the treatment with VAL201 was halted for a defined reason, whether or not the 6 standard cycles had been completed,""
in other words a stop on treatments including patients in that 6 standard cycles ?
Grace
""" Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)"""
https://clinicaltrials.gov/ct2/show/NCT02280317
result
Nevertheless, the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug. With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate."
sounds very similar ...
ATB
Bankfool ..
not here to argue ... but discuss what is in the RNS ....
i am sure those wishing to buy VAL would be very interested in why you and others are trying to stop any discussion ..
I have no Agenda
Grace
How do you explain this statement from the RNS
Nevertheless, the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug. With this data in hand, future studies will investigate optimal dosing strategies for VAL201
what does that mean ........ increase would require a Step up via a """phase 1 approach """
if you change how you dose, timing etc ... that would require specifics to identify which is the best approach
this is exactly what i mean about "deficits"
VAL decided to RNS without the full results ........ and a full explanation ..
so lets say they had "stable decease" ............. for how long ?
Don't talk rubbish ....... everything i am posting is in the Public domain ... I don't need to generate Fake news, what i am concerned about is the sector .. we want investors involved in clinical trials, i have battled on the other share for years about the quality of the science and the importance of investing on the back of good data, because without that data you increasing the Risk 100 x and you are more likely to lose your shirt than buy more ...
SNG ... the man mentions .. Good results, and effectively they are running a live phase 3 trial in Covid patients and i am positive if those results scale up it will get approval .. (interferon Beta) as it does appear Covid is blocking the first stages of the immune systems response .. good on them
why ... the CEO developed 401 ....... which produced what exactly ....... ? 7 patients treated instead of 25
was a Lung Cancer treatment that got downgraded to palliative care ... even Grace accepts .. little bit suspect
I posted on here at 7p before consolidations and the explosion in shares ....... ""this trial result is dreadful""
but that was not acceptable to the rampers ...